Director/PDMR Shareholding
August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transaction by person discharging managerial responsibilities
+--+---------------------------------------------------------------------------+ |1.|Details of the person discharging managerial responsibilities ('PDMR') / | | |person closely associated them ('PCA') | +--+----------------------------------+----------------------------------------+ |a)|Name |Bill Mordan | +--+----------------------------------+----------------------------------------+ |2.|Reason for the notification | +--+----------------------------------+----------------------------------------+ |a)|Position / status |General Counsel and Company Secretary - | | | |PDMR | +--+----------------------------------+----------------------------------------+ |b)|Initial notification / amendment |Initial notification | +--+----------------------------------+----------------------------------------+ |3.|Details of the issuer, emission allowance participant, auction platform, | | |auctioneer or auction monitor | +--+----------------------------------+----------------------------------------+ |a)|Name |Shire plc | +--+----------------------------------+----------------------------------------+ |b)|LEI |54930005LQRLI2UXRQ59 | +--+----------------------------------+----------------------------------------+ |4.|Details of the transaction(s): section to be repeated for (i) each type of | | |instrument; (ii) each type of transaction; (iii) each date; and (iv) each | | |place where transactions have been conducted | +--+----------------------------------+ | |a)|Description of the financial |Shire plc American Depositary Shares | | |instrument, type of instrument |('ADSs') | | | | | | | | | | | | | | |Identification code |ISIN: US82481R1068 | +--+----------------------------------+----------------------------------------+ |b)|Nature of the transaction |Acquisition of ADSs | +--+----------------------------------+--------+-------------------------------+ |c)|Price(s) and volume(s) |Price(s)| Volume(s) | | | +--------+-------------------------------+ | | |$141.56 | 1,000 | +--+----------------------------------+--------+-------------------------------+ |d)|Aggregated information |N/A (single transaction) | | | | | | |- Aggregated volume | | | | | | | |- Price | | +--+----------------------------------+----------------------------------------+ |e)|Date of the transaction |August 22, 2017 | +--+----------------------------------+----------------------------------------+ |f)|Place of the transaction |NASDAQ Global Select Market | +--+----------------------------------+----------------------------------------+
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire
B2QKY05R16
Copyright RTT News/dpa-AFX